Earnings
Shoe Station misses Q2 EPS and sales, cuts full-year outlook
Shoe Station Group reported a 33% miss on diluted EPS and a 7.2% revenue decline in Q2 fiscal 2026, citing weak foot traffic and compressed margins, then lowered its full-year guidance.
Permian Resources Surges to All-Time High on Earnings Beat and Raised Guidance
Permian Resources shares hit $24.15, a new high, after the E&P company reported second-quarter earnings and revenue that topped estimates and generated record free cash flow.
Nuveen Dividend Advantage Municipal Fund Hits 52-Week Low at $11.10
The municipal bond ETF marked its lowest price in a year as the broader muni market faces headwinds from interest-rate volatility and softening investor demand.
West Pharmaceutical Raises Full-Year Guidance on Strong HVP Demand
West Pharmaceutical Services lifted full-year organic revenue growth forecast to 10-11% and widened margin expansion targets, citing robust demand for high-value elastomer components and European Annex 1 regulatory tailwinds.
Lincoln Electric Says Recovery Builds as Q2 Volumes Rise First Time in Nine Quarters
The welding-equipment maker reported first volume growth since Q1 2024, with Q3 incremental margins tracking in the low 20s amid persistent inflation and a narrowing price-cost gap.
Syndax's Revuforj Revenue Tops $200M Run Rate as Market Share Surges to 85%
Revumenib hits well-north-of-$200M annual run rate in its second year with 85%+ share of the relapse-refractory AML KMT2A/NPM1 space.
Merit Medical outlines strategic review and 2026 guidance at Wells Fargo conference
CEO Martha Aronron said the review puts all options on the table as the company targets 7%‑7.5% revenue growth, 21%‑21.5% operating margin and 11%‑14% EPS growth for 2026.
Builders FirstSource Hits 52-Week Low as Earnings Miss, Exec Departs
Shares of BLDR fall to $58.13 after Q2 adjusted EPS dropped 51% year over year, missing forecasts, while its president of technology and digital solutions departs.
Vince Reports Q2 Earnings Beat, OVO Deal Lifts Outlook
Vince Holding reported adjusted EPS of $1.02 against a $0.16 estimate, driven by strong top-line growth. An August OVO acquisition adds upside potential with plans to build a $100M+ business.
Designer Brands beats Q2 2026 EPS, lifts full-year outlook
Adjusted EPS rose to $0.34, topping estimates, while revenue slipped 1% to $730.6 million. The retailer raised its 2026 EPS guidance to $0.47‑$0.52 and expects flat to modest sales growth.
MasterCraft Q4 sales surge 63% on Chaparral acquisition; shares rise premarket
Boat maker beats on top and bottom line as integration of Chaparral and Robalo brands lifts results; shares climb 5.75% in pretrade.
Yuanbao Insurance Posts Strong Q2 2026 Results, Shares Rise on Growth
Yuanbao Insurance reported a 30% revenue jump and 36% profit growth for Q2 2026, driven by AI-powered operations and new product lines, while shares climbed in premarket trading.
R&S net profit drops 25% in first half on weaker demand
Transformer maker R&S reported a 25.4% decline in H1 net profit to CHF 22.4 million, with revenue down 13% and EBITDA margin falling to 19% from 21.3%. Full-year guidance was reaffirmed.
Swiss Re Shares Hold Steady at CHF 138.75 as Investors Assess Half-Year Results
The reinsurer's shares traded at CHF 138.75 on the SIX Swiss Exchange following a strong first-half performance marked by growth in property-casualty reinsurance and corporate solutions.
Avalo Therapeutics outlines Phase III plans for IL-1 beta blocker
The Philadelphia-based biotech detailed its lotus trial data and Phase III design for hidradenitis suppurativa at the Cantor Fitzgerald conference.
Empire Company Reports Record Q1 EPS of CAD 1.04, Stock Flat
Canada's largest food distributor posted record quarterly earnings but a slight revenue miss left shares unmoved in premarket trading.
hVIVO Reports H1 Loss as Record Orderbook Signals Turnaround Ahead
Contracted orderbook more than doubles to £72m, but revenue drops 32% to £16.3m and adjusted EBITDA slips to a £4.5m loss. Full-year guidance points to low single-digit loss.
Inditex reports profit miss despite strong August sales
Inditex said its earnings fell short of expectations even as August sales remained robust.
Medicus Pharma Posts Phase 2 Results for Gorlin Syndrome Skin Cancer Drug
The company posted results from its SKNJCT-003 trial of SkinJect for nodular basal cell carcinoma, selected a 200-microgram dose for further development and said an FDA-authorized Phase 2b study is underway.
215A posts stronger Q1 2026 sales as new plan gains traction
Japan staffing firm Timee reports 24.8% sales growth to JPY 10.044 billion in Q1 fiscal 2026, driven by its long-term part-time support hire program launched in August 2025.
Labcorp reaffirms 2026 outlook, sets multi-year growth targets through 2029
Labcorp Holdings kept its full-year 2026 guidance intact while outlining compound revenue growth of 5-8% and adjusted EPS growth of 8.5-11.5% through 2029.
hVIVO posts H1 loss, cuts FY2026 revenue guidance as order book hits record
The UK‑based clinical‑services firm reported GBP 16.3 million revenue in H1 2026, a 32% YoY drop, and revised full‑year revenue to GBP 47 million while expanding its order book to GBP 72 million.
Fever-Tree Shares Drop 5% Despite US Growth Momentum in H1 Results
Fever-Tree reported 8% constant-currency revenue growth and record U.S. market share, but shares fell 5.13% as U.S. margin contraction and valuation headwinds weighed on investors.
FirstRand shares rise after UK charge blunts H2 profit beat
FirstRand reported normalized earnings up 16% for FY2026, but a GBP 518 million UK motor finance provision cut headline profit 5%. Shares climbed 3% on stronger core performance.